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Vasculogenesis and Angiogenesis in VEGF Receptor-1 Deficient 
Mice
Vivienne C. Ho and Guo-Hua Fong
Center for Vascular Biology and Department of Cell Biology University of Connecticut Health 
Center, Farmington, Connecticut 06030
Abstract
Vascular endothelial growth factor receptor-1 (VEGFR-1)/Flt-1 is a transmembrane tyrosine 
kinase receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). VEGFR-1 is an 
enigmatic molecule whose precise role in postnatal angiogenesis remains controversial. Although 
many postnatal and adult studies have been performed by manipulating VEGFR-1 ligands, 
including competitive binding by truncated VEGFR-1 protein, neutralization by antibodies, or 
specific ligand overexpression or knockout, much less is known at the level of the receptor per se, 
especially in vivo. Perplexingly, while VEGFR-1 negatively regulates endothelial cell 
differentiation during development, it has been implied in promoting angiogenesis under certain 
conditions in adult tissues, especially in tumors and ischemic tissues. Additionally, it is unclear 
how VEGFR-1 is involved in vascular maturation and maintenance of vascular quiescence in adult 
tissues. To facilitate further investigation, we generated a conditional knockout mouse line for 
VEGFR-1 and characterized angiogenesis in postnatal and adult mice, including angiogenesis in 
ischemic myocardium. We discuss these findings in the context of the interplay between VEGF 
family members and their receptors, and summarize various mouse models in the VEGF pathway.
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1. Introduction
VEGFR-1 was originally identified by Shibuya and coworkers as fms-like tyrosine kinase, 
or Flt-1 (1). Subsequent studies demonstrated that Flt-1 was a receptor for vascular 
endothelial growth factor (VEGF-A) (2). Flt-1, now also known as VEGFR-1, was found to 
be most strongly expressed in vascular endothelial cells (3). The Vegfr-1 gene contains two 
alternative polyadenylation sites: one within intron 13 and another after exon 30, the last 
exon of the gene. The alternative transcripts encode two isoforms: soluble VEGFR-1 
(sVEGFR-1) which lacks the transmembrane (TM) and cytoplasmic kinase domains, and a 
full length transmembrane VEGFR-1 which displays weak kinase activity upon VEGF-A 
binding (4). A related receptor, fetal liver kinase (Flk-1) was also identified as a VEGF-A 
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receptor and is now commonly referred to as VEGFR-2 (5). Intriguingly, although VEGF-A 
binds to VEGFR-1 with an approximately ten-fold higher affinity than it does to VEGFR-2, 
the former interaction only weakly activates VEGFR-1 kinase activity, whereas VEGFR-2 
exhibits robust tyrosine kinase activity upon VEGF-A binding (6). In vitro studies indicated 
that VEGFR-2 but not VEGFR-1 is required for endothelial cell proliferation, migration and 
survival (7-9).
To assess its biological function, Vegfr-1 null (-) allele was created by replacing the signal 
peptide coding sequence in exon 1 with E. coli lacZ gene (10). Vegfr-1-/- (flt-1-/-) embryos 
displayed uncontrolled endothelial cell differentiation, with an overcrowded population of 
endothelial cells forming severely disorganized vascular patterns, and died in utero at E8.5 
(10, 11). In contrast, Vegfa+/- as well as Vegfr-2-/- (flk-1-/-) mutations severely limited 
endothelial cell differentiation and prevented the formation of vascular structures, resulting 
in embryonic lethality at E8.5-9.5 (12-15). Consistent with a requirement of VEGFR-2 
signaling in vascular development, double knockout of neuropilin-1 and -2, which are 
VEGF-A co-receptors with roles in facilitating VEGF-A/VEGFR-2 interaction, led to 
Vegfr-2 null-like vascular defects (16). However, knockout of VEGFR-1 specific ligands 
including VEGF-B and placental growth factor (PlGF) did not have apparent impacts on 
embryonic vascular development (17-19).
In contrast to the embryonic lethality of Vegfr-1-/- knockout, targeted deletion of kinase 
domain alone did not affect vasculogenesis or angiogenesis in either embryos or adult 
tissues, suggesting that increased endothelial differentiation in Vegfr-1-/- embryos was 
unlikely due to lack of VEGFR-1 kinase signaling. Instead, a more likely function of 
VEGFR-1 may be to prevent VEGF-A/VEGFR-2 interaction through a sink-like function 
mediated by its high affinity binding to VEGF-A (20). Deletion of both VEGFR-1 TM and 
kinase domains led to in utero death at E8.5-9.0, with few blood vessels present in 
embryonic and yolk sac tissues (21). This phenotype suggests that the secretion of an 
additional amount of truncated VEGFR-1 may have further reduced VEGF-A/VEGFR-2 
interaction to a level insufficient for normal development. Consistent with this 
interpretation, a previous study indicated that secreted VEGFR-1 may compete for VEGF-A 
more effectively than membrane-anchored VEGFR-1 (22). Alternatively, it is also possible 
that the TM domain in VEGFR-1 may be required for facilitating VEGFR-2 signaling by yet 
unknown mechanisms (21). Positive regulatory roles for VEGFR-1 signaling have been 
suggested in other studies as well. For example, loss of PlGF expression was associated with 
compromised angiogenesis in ischemic myocardium, implying that PlGF-induced VEGFR-1 
signaling or heterodimerization with VEGFR-2 may be important for angiogenesis (23).
In addition to the Vegfr-1 knockout studies, many other related studies have been carried 
out, targeting different VEGF family members, isoforms, or receptors. In Table 1, we 
present a list of knockout mice in the VEGF pathway, which summarizes main phenotypes 
associated with different alleles.
Recently, we reported that Cre-loxP mediated Vegfr-1 knockout in neonatal and adult mouse 
tissues led to increased angiogenesis of structurally and functionally normal blood vessels 
(24). Consistent with elevated angiogenesis, both tip cell formation and endothelial cell 
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proliferation were increased. These changes were at least partially dependent on increased 
VEGFR-2 abundance and signaling, which may in turn result from increased VEGF-A 
accessibility in VEGFR-1 deficient tissues. Our findings indicate that a VEGF-A sink 
function appears to be the predominant role of VEGFR-1 during postnatal angiogenesis.
2. Materials
2.1. Recombinant DNA
1. VEGFR-1/Flt-1 BAC clone (RPCI-23-412O20, abbreviated as FltBac20)(ResGen, 
Life Technology, Grand Island, NY, USA) contained a 211,423 base pair (bp) 
fragment of chromosome 5 in the EcoRI site of the pBACe3.6 vector (25). The 
FltBac20 fragment starts from 2,755 bp downstream of exon 1, spans the rest of the 
Vegfr-1 gene (including most of the 25,253 bp long intron 1), and continues into 
the pomp gene.
2. E. coli strains (EL250 and EL350) (gifts from N. Copeland, NIH, Bethesda, MD, 
USA (26))
3. pL253 (gifts from N. Copeland (26)).
4. Molecular biology reagents, including competent cells, restriction enzymes, 
dNTPs, Taq polymerase, T4 DNA ligase and Klenow fragment, Pfu Turbo.
5. Gel extraction kits (Qiagen, Germantown, MD, USA).
6. Oligonucleotide primers.
2.2. ES cell culture
1. R1 embryonic stem (ES) cells from 129/S6 strains (gift from A. Nagy, Samuel 
Lunenfeld Research Institute, Toronto, Canada).
2. G4 embryonic stem (ES) cells, a hybrid cell line of C57BL/6 and 129/S6 strains 
(gift from A. Nagy, Samuel Lunenfeld Research Institute, Toronto, Canada).
3. ES cell media contained DMEM (Life Technologies, Grand Island, NY, USA) 
supplemented with 15% FBS (STEMCELL Technologies, Vancouver, Canada), 
streptomycin/penicillin, β-mercaptoethanol and leukemia inhibitory factor.
4. Mouse embryonic fibroblasts (MEFs).
5. Geneticin (G418/neomycin).
6. Ganciclovir.
7. FLPe expression vector (pCAGGSFLPe, gift from S. Dymecki, Harvard Medical 
School, Boston, MA, USA).
2.3. Tissue preparation and histology reagents
1. Embryos and yolk sac membranes.
2. Glutaraldehyde fixation solution (0.2% glutaraldehyde, 5 mM EGTA (pH 7.3), 2 
mM MgCl2, and 0.1 M sodium phosphate (pH 7.3)).
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3. Embryos/yolk sac washing solution: 100 mM phosphate buffer (pH7.3) 
supplemented with 2 mM MgCl2, 0.01% deoxycholate, and 0.02% Nonidet-P40.
4. X-Gal staining solution, prepared by 1:25 dilution of 5-bromo-4-chloro-3-indolyl-
β-D-galactoside (Biosynth AG, Switzerland) from a 25 mg/ml stock in formamide 
into 100 mM phosphate buffer (pH7.3) containing 5 mM potassium ferrocyanide 
and 5 mM potassium ferricyanide.
5. Ethanol gradient, consisting of a series of ethanol solutions at 70%, 85%, 85%, and 
100% of ethanol.
6. Blocking solution: 1% BSA, 5% normal goat serum (Vector Laboratories, 
Burlingame, CA, USA) in PBST (phosphate buffered saline (PBS) supplemented 
with 0.3% Triton X-100).
7. 4% paraformaldehyde.
8. Zinc fixation solution (0.05% Calcium Acetate, 0.5% Zinc Acetate, 0.5% Zinc 
Chloride, 100 mM Tris-Cl, pH 7.4).
9. Antibodies: Anti-α-SMA conjugated to FITC (1:250, Sigma-Aldrich), anti-NG2 
(1:300; Millipore), goat anti-rabbit conjugated to Alexa Fluor®-488 (1:300; 
Molecular Probes, Life Technologies, Grand Island, NY, USA), rat anti-mouse 
platelet/endothelial cell adhesion molecule (PECAM)-1 (Mec13.3; BD Biosciences, 
San Jose, CA, USA), biotinylated goat anti-rat IgG-HRP (Jackson 
ImmunoResearch, West Grove, USA), goat anti-PECAM-1 (M-20, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), biotinylated donkey anti-goat IgG-HRP 
(Jackson ImmunoResearch, West Grove, USA).
10. Isolectin B4 (IB4)-Alexa-594 or IB4-Alexa Fluor®-488 (1:200, Molecular Probes, 
Life Technologies, Grand Island, NY, USA).
11. ABC and DAB kits (Vector Labs, Burlingame, CA, USA).
12. Retinal mounting media (50% glycerol in PBS).
13. Fisher finest Premium Cover Glasses.
14. Nail polish (Revlon).
2.4. Mice
1. All procedures used in handling mice were approved by the Animal Care 
Committee at the University of Connecticut Health Center in compliance with 
Animal Welfare Assurance.
2. CD1 mice (Charles River, Wilmington, MA, USA).
3. Vegfr-2+/- (Flk-1+/-) mice (Jackson Laboratories, Bar Harbor, ME, USA).
4. EIIa-Cre transgenic mice (Jackson Laboratories, Bar Harbor, ME, USA).
5. Rosa26CreERT2 line driving ubiquitous expression of tamoxifen inducible CreERT2 
(gift from A. Joyner, NYU).
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6. Tamoxifen (20 mg/ml in corn oil).
3. Methods
3.1. Generation of Vegfr-1 germline null allele
1. The Vegfr-1 targeting vector was generated by replacing the signal peptide coding 
sequence in exon 1 with the E. coli lacZ gene (Figure 1). This replacement resulted 
in the disruption of translational initiation and led to a reading-frame shift in 
downstream sequences.
2. The targeting vector was introduced into R1 ES cells by electroporation, and plated 
out in ES cell media on a layer of neomycin resistance MEFs. Approximately 36 
hours later, selection for Geneticin (150 μg/ml) and Ganciclovior (2 μM) resistance 
was started.
3. At 7 to 8 days of selection in Geneticin and Ganciclovior containing ES cell media, 
single colonies were picked, expanded, and duplicated.
4. DNA was purified from ES cells, digested by PvuII, and analyzed by Southern 
blotting according to Joyner et al (27). The probe hybridized to a genomic region 
immediately downstream from the 3’ end the 3’ homology region.
5. Targeted ES cell clones were identified based on Southern blotting data, and 
recovered from frozen duplicate of ES cells.
6. DNA was isolated from recovered cultures, and digested by EcoRV.
7. Southern blotting was performed using a probe hybridizing to a region immediately 
upstream to the 5’ end of the 5’ homology arm.
8. Correctly targeted ES cells were used to generate chimeras by in vitro aggregation 
with CD1 morula embryos (27).
9. Germline transmission of the targeted Vegfr-1 allele was achieved by crossing 
chimeric male with CD1 females.
3.2. Generation of Vegfr-1 floxed allele
1. To construct the targeting vector, a 14.8 kb fragment encompassing exon 3 and 
flanking areas was transferred from FltBac20 into pL253 by γ-Red mediated 
recombineering (26), resulting in pL253Flt as shown in Figure 2A. Subsequently, a 
recombination cassette containing floxed exon 3 and Frt-flanked neomycin (Figure 
2B) was integrated into pL253Flt to replace exon 3, resulting in the targeting vector 
as shown in Figure 2C.
2. The targeting vector and plasmids generated at intermediate steps were sequenced 
using big dye sequencing through the Molecular Core facility at UConn Health 
Center, Farmington, CT, USA.
3. The targeting vector was introduced into G4 ES cells (28) (29) by electroporation 
to allow homologous recombination as shown in Figure 3A. Methods of ES cell 
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culture and screening are essentially the same as steps 2-7 in section 3.1, except 
that ES cell DNA was digested by HindIII for Southern blotting with 3’ probe.
4. ES cells carrying a targeted allele (Figure 3B) were transfected with 
pCAGGSFLPe, plated out on MEF at several thousand cells per 10 cm plate.
5. A small fraction of plated cells survived and formed single colonies, which were 
picked and cultured in 96 well plates, and subsequently duplicated in two 96 well 
plates, one of which contained Geneticin (100 μg/ml).
6. ES clones whose Frt flanked neo cassette was deleted by Flpe (Figure 3C) were 
expanded, and used for in vitro aggregation with wild-type morula embryos. 7. 
Resultant chimeric mice were crossed with CD1 mice for germline transmission of 
the floxed allele.
3.3. In vivo validation of the floxed allele
1. To determine if deletion of floxed exon 3 inactivates the Vegfr-1 gene, Vegfr-1+/flox 
mice were crossed to EIIaCre mice, resulting in Vegfr-1 +/Δ germline where Δ is an 
exon 3-deleted allele.
2. Vegfr-1 +/Δ mice were then crossed with Vegfr-1+/- mice. Embryos were dissected 
at E8.5, fixed in glutaraldehyde fixation solution, rinsed in embryo washing 
solution for 3 times (~10 minutes each), and incubated in X-Gal staining solution 
for up to 4 hours at 37°C. Stained specimens were photographed on Leica 
dissection microscope outfitted with a CoolSnap digital camera.
3. X-gal stained embryos and yolk sacs were dehydrated through an ethanol gradient 
followed by toluene, and then embedded in paraffin. Sections were cut at 5 μm, 
counterstained with nuclear fast red, and imaged on a Zeiss Axioskop microscope.
3.4. Analysis of angiogenesis in neonatal mice
1. Vegfr-1flox/flox/Rosa26CreERT2/+ mice were generated by successive rounds of 
crosses between floxed Vegfr-1 and Rosa26CreERT2/+ mice.
2. Vegfr-1flox/flox/Rosa26CreERT2/+ and Vegfr-1flox/flox mice were treated with 
tamoxifen by oral gavage (40 mg/kg body weight).
3. Retinas were isolated from tamoxifen-treated neonatal mice as follows: Eyes were 
removed with curved forceps from euthanized mice, rinsed with ice cold phosphate 
buffered saline (PBS) and then fixed with 4% paraformaldehyde (PFA) for 35 
minutes on ice. After rinsing three times with PBS, whole retina cups were isolated, 
and incubated for 1 hour in blocking solution.
4. To visualize retinal blood vessels, retinas were stained with IB4-Alexa-594 or IB4-
Alexa Fluor®-488 (1:200 dilution in the blocking solution supplemented with 0.5 
mM MgCl2 and 0.5 mM CaCl2).
5. Retinas were also analyzed by immunofluorescence staining with anti-α-SMA 
conjugated to FITC (1:250) to monitor the recruitment of vascular smooth muscle 
cells.
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6. To visualize pericytes covering microvessels, retinas were stained with anti-NG2 
(1:300) followed by anti-rabbit IgG- Alexa Fluor®-488 (1:300).
7. Stained retinas were flat-mounted onto glass slides by 4 incomplete radial 
incisions, placed in mounting media under cover slips, and sealed with nail polish. 
Mounted retinas were imaged using either Zeiss Pascal or Zeiss 510 confocal 
microscope system.
8. Angiogenesis in other tissues such as the heart and liver were evaluated by anti-
PECAM-1 (CD31) immunohistochemical staining or IB4-Alexa-594 (1:200). IHC 
stained slides were counterstained with Haematoxylin QS, and imaged on a Zeiss 
Axioskop microscope. Immunofluorescence image were taken on a Zeiss Pascal 
microscope system.
9. Angiogenic activity was quantified by evaluating the number of branching points 
located within a defined field of view as well as by calculating percent areas 
occupied by vascular structures.
3.5. Analysis of angiogenesis in adult tissues
1. At 6 weeks of age, Vegfr-1flox/flox/Rosa26CreERT2/+ mice and their Vegfr-1flox/flox 
controls were treated with tamoxifen by oral gavage (40 mg/kg).
2. Vascular structures were identified by anti-CD31 IHC (for non-retinal tissues) or 
IB4- Alexa-594 (for retinas) staining, and quantified by counting branching points 
and percent area occupied by vascular structures.
3. Vascularization was also evaluated in ischemic myocardium following the ligation 
of the left anterior descending coronary artery (LAD)(30).
3.6. Mechanisms of angiogenesis
1. Increased angiogenesis was observed following Rosa26CreERT2-mediated deletion 
of exon 3 in both neonatal and adult tissues. The mechanisms of increased 
angiogenesis were investigated by two methods, described in 3.6.2 and 3.6.3.
2. VEGFR-2 selective inhibitor, SU1498, was injected intraperitoneally, 
approximately 30mg/kg on a daily basis at alternating injection sites for 14 days 
between P7 and P20.
3. A single Vegfr-2– allele was introduced into Vegfr-1flox/flox/Rosa26CreERT2/+ 
background, and angiogenesis was quantified after tamoxifen-induced Vegfr-1 
disruption.
4. The number of tip cells was compared between floxed controls and mice deficient 
for VEGFR-1. Tip cells in P5 retinal tissues were identified as IB4 positive cells 
located at the vascular front, with extensive filopodia, and containing TOPRO3-
stained cell nuclei. The observation of tip cells was facilitated by z-stack confocal 
imaging.
5. The mechanism of increased tip cell formation was investigated by injecting anti-
VEGF-A neutralizing antibody into the vitreous cavity.
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6. Proliferating endothelial cells in P5 retinas were identified by 5’-bromo-2’-
deoxyuridine (BrdU) incorporation assay. Neonatal mice were injected with BrdU 
intraperitoneally at 0.12 g/kg, and euthanized after 90 minutes for retina dissection. 
Double staining for endothelial cells (IB4-Alexa-594) and proliferating cells (anti-
BrdU) was performed as described previously (24). Double positive cells were 
visualized by confocal imaging.
4. Summary
While vascular structures are highly disorganized in germline Vegfr-1-/- or Vegfr-1 -/Δ 
embryos (Figure 4)(23), somatic knockout of Vegfr-1 in neonatal and adult mice led to 
elevated angiogenesis (Figure 5), characterized by increased vascular branching points, tip 
cell formation and endothelial cell proliferation (23). Notably, blood vessels resulting from 
somatic Vegfr-1 knockout were properly associated with vascular smooth muscle cells and 
pericytes, maintained normal baseline vascular permeability, and fully supported circulatory 
function, although vascular permeability was increased in response to excessively high 
levels of exogenous VEGF-A (24).
In spite of apparently contrasting morphological phenotypes between germline and somatic 
Vegfr-1 knockout mice, a common feature is increased number of endothelial cells. We 
hypothesize that different morphological appearances might be a manifestation of distinct 
tissue contexts in embryonic and postnatal tissues, rather than fundamental differences in 
molecular and cellular mechanisms.
Molecularly, increased angiogenic activities in somatic Vegfr-1 knockout mice were 
accompanied by elevated VEGFR-2 protein level and tyrosine phosphorylation without 
apparent increases in VEGFR-2 mRNA. The hyperactive angiogenesis could be reverted 
back towards normal levels by manipulations that diminish VEGFR-2 expression and 
signaling or suppress VEGF-A bioactivity, including reduction of Vegfr-2 gene dosage, 
injection of VEGFR-2 selective kinase inhibitor, or VEGF-A neutralization by anti-VEGF-
A. These findings suggest that increased angiogenesis was at least partially caused by loss of 
VEGF-A sink function rather than loss of VEGFR-1 kinase signaling activity.
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Figure 1. Flt-1/VEGFR-1 targeting strategy
A Flt-1/VEGFR-1 targeting vector containing the lacZ (blue box) and neo (green box) genes 
was used to replace a small fragment (gray box) containing the spcs (signal peptide coding 
sequence) and the sds (splicing donor site). The targeting vector contained a 6.5 kb 5’ 
homology arm and 1.6 kb 3’ homology arm. Purple box, 5’ untranslated region; red box, 
polyadenylation signal (pA); yellow box, thymidine kinase negative selection gene (TK). 
The resulting targeted allele is shown at the bottom.
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Figure 2. Construction of VEGFR-1 conditional targeting vector by γ-Red-mediated homologous 
recombination (recombineering)
A. pL253Flt plasmid, consisting of a pL253 plasmid backbone and a 14.8 kb fragment of the 
Vegfr-1 gene encompassing exons 2 and 3 (labeled light blue boxes) and associated intronic 
sequences. Navy blue box, ampicillin resistance gene (amp); yellow box, thymidine kinase 
negative selection marker (TK, ganciclovir resistance); bright blue bars (a and b) represent 
the short homology sequences where homologous recombination occurred between 
FltBac20 and pL253-based retrieval vector, with their external ends (relative to exons) 
marking the 5’ and 3’ ends of the retrieved fragment. Purple bars represent intronic 
fragments (c, intron 2; d, intron 3) used as homology arms for recombineering with 
pL253Flt. B. Recombination cassette containing the following elements in the 5’ to 3’ 
direction: an intron 2 fragment (purple bar, c ), loxP (triangle), ~150 bp sequence from the 
end of intron 2, exon 3 (light blue box), ~ 150 bp from the beginning of intron 3, a second 
loxP site, neomycin resistance cassette (green box) with polyadenylation signal (pA, red 
box) at its end and flanked by a pair of Frt sites (orange boxes), and an intron 3 fragment 
(purple, d). Purple bars labeled c and d mediate integration into pL253Flt by homologous 
recombination. C. The VEGFR-1 conditional targeting vector generated by homologous 
recombination between pL253Flt (shown in A) and the recombination cassette (shown in B). 
Not I, site of linearization before electroporation into ES cells.
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Figure 3. Flt-1/VEGFR-1 conditional knockout targeting strategy
A. The conditional VEGFR-1 targeting vector contained a 9.6 kb 5’ homology arm, floxed 
exon 3, an Frt (F, orange boxes) flanked neomycin resistance cassette (green box with a 
polyadenylation sequence (red box) at its 3’ end), a 4.7 kb 3’ homology arm, thymidine 
kinase cassette (TK, yellow rectangle), and the vector backbone (not shown). B. floxN allele 
which is the product of homologous recombination as shown in A. C. flox allele, generated 
by in vitro removal of the neomycin cassette by transfecting targeted ES cell clones with a 
Flpe expression vector.
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Figure 4. X-gal stained Vegfr-1+/- and Vegfr-1-/- yolk sacs
A and B. Whole mount (A) and histological section (B) of Vegfr-1+/- yolk sac specimens. C 
and D. Vegfr-1-/- yolk sac images. Note that in Vegfr-1-/- mice, discrete vascular structures 
are difficult to identify. All scale bars are 100 μm.
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Figure 5. Effects of somatic Vegfr-1 knockout on retinal angiogenesis
Rows A and B. Vegfr-1flox/flox and Vegfr-1flox/flox/Rosa26CreERT2/+ mice were treated with 
tamoxifen by oral gavage for 3 days between P1 and P3, and retinal angiogenesis was 
examined at P21 by IB4-Alexa 594 staining of flat mounted retinas. Vegfr-1Δ/Δ represents 
tamoxifen-treated Vegfr-1flox/flox/Rosa26CreERT2/+ mice. GCL, ganglion cell layer; IPL, 
inner plexiform layer; OPL, outer plexiform layer. C and D. Retinal cross sections from 
Vegfr-1+/- and Vegfr-1Δ/- neonatal mice, the latter of which was generated by tamoxifen 
treatment of Vegfr-1flox/-/Rosa26CreERT2/+ mice. Note more abundant presence of X-gal 
positive vascular structures in D. All scale bars are 50 μm.
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Table 1
Summary of mouse models in the VEGF pathway
Gene Type Genotype Phenotype Ref
Vegfa germline heterozygous knockout Vegfa+/− Vascular deficiency, 
embryonic lethality at 
E9.5
(12, 13)
Vegfa global conditional VegfaloxP/loxP/MX-1-Cre Impaired postnatal 
growth; some lethality
(31)
Vegfa germline hypomorphic allele Vegflo/lo Impaired haematopoietic 
and endothelial 
differentiation
(32)
Vegfa Vegfa 164/188 deletion Vegfa120/120 Reduced vascular 
growth, death before 
post-natal day 14
(33)
Vegfa Vegfa 120/188 deletion Vegfa164/164 Essentially normal (33)
Vegfa Vegfa 120/164 deletion Vegfa188/188 Impaired arterial 
development, ~half of 
embryos die in utero
(33)
Vegfa endothelial knockout Vegfalox/lox/VE-CAD-Cre Endothelial cell 
apoptosis, premature 
postnatal death
(34)
Vegfr-1/Flt-1 germline knockout with lacZ 
reporter
Flt-1−/− (Flt-1lcz/lcz) Excessive endothelial 
cell production, lethal at 
E8.5
(10)
Vegfr-1/Flt-1 kinase domain knockout Flt-1(TK−/−) No apparent vascular 
defects
(20)
Vegfr-1/Flt-1 global conditional Vegf-1flox/flox/Rosa26CreERT2/+ Increase in postnatal 
angiogenesis
(24)
Vegfr-1/Flt-1 Knockout in podocytes Nphs1-Cre+Flt1flox/flox Reorganization of 
podocyte cytoskeleton, 
Kidney failure
(35)
Vegfr-1/Flt-1 germline TM domain knockout Flt-1TM-TK/TM-TK Reduced vascular 
development, death at 
E8.5 in some embryos
(21)
Vegfr-2/Flk-1 germline knockout with lacZ 
reporter
Flk-1−/− (Flk-1lcz/lcz) Lack of vascular 
development, lethality at 
E8.5-9.5
(14)
Vegfr-2/Flk-1 germline Y1173F mutation Flk-11173F/1173F Lack of vascular 
development, death at 
E8.5-E9.5
(36)
Vegfr-2/Flk-1 endothelial knockout Vegfr-2floxed/floxed/Cdh5(PAC)CreERT2T/+ Reduced sprouting (37)
Vegfr-3/Flt-4 germline knockout Vegfr3−/− Vascular remodeling 
defects, death at 
E9.5-10.5
(38)
Vegfr-3/Flt-4 endothelial knockout Vegfr-3floxed/floxed/PdgfbiCreT2 Reduced tip to stalk cell 
conversion, hyper-
sprouting
(39)
Plgf germline knockout Plgf−/− Normal development, 
defective pathological 
angiogenesis
(19)
Vegfb germline knockout Vegfb−/− Modest heart defects; 
reduced fat uptake
(17, 18, 40)
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Gene Type Genotype Phenotype Ref
Nrp-1 germline knockout Nrp1−/− Vascular malformation, 
nerve defects, death at 
E12.5 -13.5
(41-43)
Nrp-2 germline knockout Nrp2−/− Nerve guidance and 
innervation defects
(44, 45)
Nrp-1/Nrp-2 germline double knockout Nrp1−/−/Nrp2−/− Lack of vascular 
development, embryonic 
lethality at E8.5
(16)
Vegfc germline knockout Vegfc−/− (lcz) Lack of lymphatic 
vessels, death at 
E15.5-17.5
(46)
Vegfd germline knockout Vegfd−/− (lcz) Essentially normal (47)
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